NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two patient registries on its proprietary NORD® IAMRARE® platform. This significant initiative is designed to empower rare disease patient communities by providing them with the necessary technological infrastructure and institutional support to gather critical patient-reported data, thereby advancing medical research and therapeutic development for underserved populations.
Funding and vital support for this project are made possible through the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®). The RDCA-DAP is a collaborative agreement established with the Critical Path Institute and is funded through the U.S. Food and Drug Administration (FDA). By bridging the gap between patient communities and regulatory bodies, this funding mechanism seeks to streamline the collection of real-world evidence and accelerate the characterization of rare diseases nationwide.
The nationwide call for applications represents an expansion of NORD’s ongoing commitment to supporting rare disease nonprofits and advocacy groups. Independent research studies led directly by affected communities have increasingly proven to be an invaluable source of medical data. Insights generated from studies hosted on the IAMRARE platform have historically played a pivotal role in shaping the rare disease landscape.
According to Tracey Sikora, Vice President of Research and Clinical Programs at NORD, community-led research initiatives have a profound impact on regulatory and clinical pathways. Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval, notes Sikora. These tangible successes underscore the immense value of patient-reported data in modern clinical research and drug development.
Under the terms of the new initiative, successful applicants will collaborate closely with NORD beginning in April 2027 to build, launch, and manage a dedicated patient registry tailored specifically to their rare disease community. NORD will assume responsibility for building and hosting the registry website, ensuring a secure, user-friendly digital environment for participants. In addition, NORD will provide comprehensive training and guidance to the registry sponsors throughout every phase of the project lifecycle.
The scope of support provided by NORD includes helping sponsors establish a formal registry advisory board, develop a robust study protocol, build and customize patient surveys, and successfully navigate the often complex Institutional Review Board (IRB) process. Furthermore, NORD will assist sponsors in determining transparent and secure criteria for sharing the data collected by the registry with external researchers, clinicians, and industry stakeholders, maximizing the utility of the collected information while protecting patient privacy.
Application Criteria and Timeline
Organizations interested in applying for this funding opportunity must meet established eligibility criteria designed to ensure readiness for registry implementation. The application process is currently open, providing eligible rare disease organizations an opportunity to secure this vital infrastructure support.
The submission window will close on January 10, 2027. Following a comprehensive review of all submissions, NORD will notify accepted applicants by February 1, 2027. Preparations and formal registry implementation activities are scheduled to officially commence in April 2027. Eligible organizations seeking to apply can access the application portal online. For organizations with inquiries regarding the request for applications or the submission process, NORD has established a dedicated contact channel for support.
About the NORD® IAMRARE® Platform
The NORD® IAMRARE® Platform serves as a centralized, secure digital infrastructure designed specifically to meet the unique needs of rare disease patient advocacy organizations. Currently, the platform hosts more than 55 live registries sponsored and managed by independent patient advocacy groups. By enabling these organizations to collect standardized, patient-reported data directly from individuals living with rare conditions, the platform bridges critical knowledge gaps that have historically hindered rare disease research. For additional information regarding the platform and its capabilities, interested parties can visit the official IAMRARE website.
About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)
The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®) is an FDA-sponsored initiative structured to provide a centralized and standardized technological infrastructure. The primary mission of the platform is to support and accelerate rare disease characterization, with the ultimate goal of expediting therapy development for patients who have few or no treatment options. By integrating diverse data sources into a cohesive analytical environment, RDCA-DAP empowers researchers to better understand disease progression and identify meaningful clinical endpoints. Further details regarding the program can be found through the Critical Path Institute.
About the National Organization for Rare Disorders (NORD®)
Founded in 1983, the National Organization for Rare Disorders (NORD®) is an independent, nonpartisan 501(c)(3) nonprofit organization dedicated to identifying, treating, and curing rare disorders through education, advocacy, research, and patient services. NORD represents more than 30 million Americans living with rare diseases, a population comprising thousands of distinct conditions, the vast majority of which lack FDA-approved treatments.
NORD operates in close partnership with more than 350 disease-specific member patient organizations across the United States. In addition, NORD oversees a growing network of 49 designated NORD Rare Disease Centers of Excellence, spanning over 170 academic medical centers, research institutions, and children’s hospitals nationwide. Through these collaborative networks, NORD continues to advance specialized care, foster innovative research, elevate public education, and champion policy reforms designed to create a better future for individuals and families impacted by rare diseases.
Media Contact:
For further press inquiries or additional information regarding this announcement, representatives of the media may contact Cheryl Herbert, Vice President of Marketing & Communications at NORD.
